Zoetis Inc. 10-K — AI Bull & Bear Analysis

The 2025 10-K reveals a company at a critical juncture, balancing a high-growth technological pivot against a rigid financial structure. While the shift toward AI and biologics is driving margin expansion, the company's heavy debt load and strict credit covenants create a narrow margin for error. The upcoming 2026 fiscal year alignment will be a pivotal moment for management to demonstrate operational efficiency across its global footprint. Ultimately, the investment thesis hinges on whether the continuum of care strategy can generate sufficient cash flow to service its $9.04 billion debt while continuing to fund a massive R&D engine. Investors must weigh the potential for a technology-driven re-rating against the systemic risks of product concentration and ongoing legal liabilities that could materialize as significant charges.